Lantheus Holdings Inc. (LNTH)
NASDAQ: LNTHHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 8, 1:07 PM ET
LNTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.54B
- P/E (TTM)
- 24.26
- Forward P/E
- 15.71
- EPS (TTM)
- $4.13
- Dividend yield
- None
- 52-week range
- 50.16 – 111.86
- Day range
- 100.08 – 100.33
- Volume / Avg
- 279.30K / 1.32M
- Beta
- —
- Shares outstanding
- 65.30M
- Next earnings
- Nov 5, 2026
52-week range
LNTH stock today
Lantheus (LNTH) is trading at $100.21 on Oct 8, up 0.02% (+$0.025), versus the S&P 500's 0.65% decline. At this level, LNTH sits near the top of its 52-week range of $50.16 to $111.86: 10.4% below the high, set on Jun 30, 2026 and 99.8% above the low. LNTH is up 50.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 93.2%.
Lantheus trades at 24.3x its trailing twelve-month earnings per share of $4.13. Its forward P/E of 15.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Lantheus's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Lantheus
Company profileLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Ms. Mary Anne Heino
- Headquarters
- Bedford, MA
- Employees
- 1,193
- IPO year
- 2015
- Website
- lantheus.com
Financial highlights
Full financialsIn fiscal 2025, Lantheus generated $1.54 billion in revenue, up 0.5% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $233.6 million (-25.2% year over year), for a net margin of 15.2% versus a median of 3.0% in the prior 5 years. Gross margin was 61.1% (down from 64.4%) and operating margin 20.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.54B | $1.53B | $1.30B | $935.06M | $425.21M |
| Growth | +0.50% | +18.32% | +38.65% | +119.91% | +25.28% |
| Net income | $233.56M | $312.44M | $326.66M | $28.07M | $-71.28M |
| EPS (diluted) | $3.41 | $4.36 | $4.65 | $0.40 | $-1.06 |
Analyst forecast
ForecastConsensus (10 analysts)
none
Avg. price target
$107.74+7.52%
- Strong buy 1
- Buy 2
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.01
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $1.11 vs —
LNTH news
All LNTH newsLantheus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORKAOruka Therapeutics Inc. | 77.32 | -2.75% | $5.12B | vs LNTH |
| NEOGNeogen Corporation | 11.86 | +1.54% | $2.59B | vs LNTH |
| CLDXCelldex Therapeutics Inc. | 29.21 | -4.03% | $2.29B | vs LNTH |
| NTLAIntellia Therapeutics Inc. | 12.08 | +3.16% | $1.69B | vs LNTH |
| QDELQuidelOrtho Corporation | 12.30 | -0.08% | $843.48M | vs LNTH |
| ACHVAchieve Life Sciences Inc. | 7.28 | +0.55% | $750.59M | vs LNTH |
| TKNOAlpha Teknova Inc. | 8.51 | -2.30% | $456.89M | vs LNTH |
| MYGNMyriad Genetics Inc. | 4.22 | -1.52% | $403.16M | vs LNTH |
Indexes, lists and sector
Lantheus stock FAQ
What is Lantheus's stock price today?
LNTH last traded at $100.21 as of Oct 8, 1:07 PM EDT, up 0.02% on the day. Prices are delayed at least 15 minutes.
When is Lantheus's next earnings date?
Lantheus is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.01.
What is LNTH's P/E ratio?
LNTH trades at a trailing P/E ratio of 24.26 and a forward P/E of 15.71.
Who is Lantheus's CEO?
Ms. Mary Anne Heino is the chief executive officer of Lantheus Holdings Inc., which has about 1,193 employees.
What is the LNTH 52-week high?
The 52-week high for LNTH is $111.86 and the 52-week low is $50.16. The stock is currently 10.4% below its high.